New insider Aralis James claimed ownership of 28,993 shares (SEC Form 3)

$CLAY
Blank Checks
Finance
Get the next $CLAY alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $CLAY alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CLAY

DatePrice TargetRatingAnalyst
More analyst ratings

$CLAY
Press Releases

Fastest customizable press release news feed in the world

See more
  • Mobix Labs, Inc. Closes Business Combination with Chavant Capital Acquisition Corp., Becomes Publicly Traded

    IRVINE, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mobix Labs, Inc. ("Mobix Labs" or the "Company"), a fabless semiconductor company developing disruptive next-generation connectivity technologies for 5G infrastructure, satellite communications and defense industries, today announced that its previously announced business combination with Chavant Capital Acquisition Corp. ("Chavant") (NASDAQ:CLAY) has closed, resulting in Mobix Labs becoming a publicly traded company. The business combination and all other proposals presented were approved at an extraordinary general meeting of Chavant shareholders held on December 18, 2023. In connection with the completion of the business combination,

    $CLAY
    Blank Checks
    Finance
  • Mobix Labs, Inc. and Chavant Capital Acquisition Corp. Announce Effectiveness of Registration Statement on Form S-4

    IRVINE, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Mobix Labs, Inc. ("Mobix Labs" or the "Company"), a fabless semiconductor company developing disruptive next-generation connectivity technologies for 5G infrastructure, satellite communications and defense industries, and Chavant Capital Acquisition Corp. (NASDAQ:CLAY) ("Chavant"), a publicly traded special purpose acquisition company, today announced that the U.S. Securities and Exchange Commission (the "SEC") has declared effective the Registration Statement on Form S-4 (as amended, the "Registration Statement") filed by Chavant and relating to the previously announced proposed business combination between Mobix Labs and Chavant (the "Bus

    $CLAY
    Blank Checks
    Finance
  • Mobix Labs, Inc. and Chavant Capital Acquisition Corp. Announce Filing of Registration Statement on Form S-4 in Connection With Proposed Business Combination

    IRVINE, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Mobix Labs, Inc. ("Mobix Labs" or the "Company"), an innovative provider of next generation wireless mmWave 5G and connectivity solutions, and Chavant Capital Acquisition Corp. (NASDAQ:CLAY) ("Chavant"), a publicly-traded special purpose acquisition company, announced today the filing by Chavant with the U.S. Securities and Exchange Commission ("SEC") of a registration statement on Form S-4 (the "Registration Statement") on April 7, 2023, relating to the previously announced proposed business combination of Chavant and Mobix Labs. The Registration Statement contains a preliminary proxy statement/prospectus in connection with the previousl

    $CLAY
    Blank Checks
    Finance

$CLAY
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$CLAY
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CLAY
SEC Filings

See more

$CLAY
Leadership Updates

Live Leadership Updates

See more
  • LinKinVax Appoints Dr. Jiong Ma as Independent Board Member

    An international expert in the financing and growth of high tech businesses LinKinVax, a clinical-stage biotechnology company specializing in the treatment of infectious diseases and certain forms of cancer, announces the appointment of Dr. Jiong Ma as independent board member. "As we enter the clinical stages of a number of drug candidates (HPV, Covid) resulting from our innovative vaccine platform, I am delighted to welcome Dr. Jiong Ma as an addition to our board. With a longstanding focus on the financing and growth of high tech businesses, her role will be to support us in our platform development strategy and to help us achieve our ambitions on a global scale. Dr. Jiong Ma benefits

    $AVXL
    $CLAY
    $SES
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Blank Checks
    Finance

$CLAY
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more